Biocon hikes stake in Biocon Biologics to 98%

22 Jan 2026 Evaluate

Biocon has acquired 7,18,34,691 equity shares representing 3.05% of total shareholding of its unlisted material subsidiary -- Biocon Biologics (BBL) from Mylan Inc for a consideration of $200 million. With this acquisition, the company has completed acquisition of 6.10% stake held by Mylan Inc. in BBL. Post this acquisition, the company holds around 98% of the paid-up equity share capital of BBL on a fully diluted basis.

Earlier in December, the Board of Directors had approved the acquisition of equity shares of BBL held by various Investors, including acquisition of 14,36,69,382 equity shares from Mylan Inc.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

372.65 8.10 (2.22%)
22-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1634.40
Dr. Reddys Lab 1217.15
Cipla 1371.55
Zydus Lifesciences 884.85
Lupin 2165.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×